Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:ZVRA

Zevra Therapeutics Q3 2026 Earnings Date & Estimates

Zevra Therapeutics logo
$11.39 +0.39 (+3.55%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$11.32 -0.07 (-0.57%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Zevra Therapeutics in Q3 2026

Zevra Therapeutics is expected to post earnings of $0.14 per share on revenue of $37.08 million. In the same quarter a year earlier Zevra Therapeutics reported -$0.01 per share on revenue of $26.06 million. Zevra Therapeutics last reported on August 5, 2026, posting $0.25 per share and beating the $0.11 consensus estimate. Zevra Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.14
Expected Revenue
$37.08 million
Prior-Year EPS
-$0.01
Prior-Year Revenue
$26.06 million
Expected Revenue Growth
+42.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.25 (Beat by +$0.14)
Last Quarter Revenue
$39.66 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Zevra Therapeutics Q3 2026 Earnings FAQ

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Zevra Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Zevra Therapeutics to post earnings of $0.14 per share for Q3 2026.

The consensus revenue estimate for Zevra Therapeutics is $37.08 million for Q3 2026.

Zevra Therapeutics Earnings Headlines

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated "Buy" by Wall Street Brokerages
October 8 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097853
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952147-zevra-therapeutics-miplyffa-validates-the-bull-case-europe-still-the-swing-factor
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
 |  Banyan Hill Publishing (Ad)
Reviewing Vireo Growth (OTCMKTS:VREOD) & Zevra Therapeutics (NASDAQ:ZVRA)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068556
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946250-zevra-therapeutics-inc-zvra-presents-at-morgan-stanley-24th-annual-global-healthcare
Zevra Therapeutics to Present at Upcoming Investor Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355014/16626/en/zevra-therapeutics-to-present-at-upcoming-investor-conferences.html
See More Zevra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zevra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your email.

About Zevra Therapeutics

Zevra Therapeutics (NASDAQ:ZVRA) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat. Niemann-Pick disease type C is a rare, progressive genetic disorder that affects the body’s ability to transport and process cholesterol and other lipids within cells.

The company was formed through the combination of Acer Therapeutics and KemPharm, completed in 2023. Zevra is headquartered in the United States and initially focuses its commercial activities on the U.S. rare-disease market, while continuing to advance additional development programs for serious and underserved conditions.

View Zevra Therapeutics Profile
Earnings Tools